| abstract |
The disclosure provides methods of using inhibitors of chaperone proteins, such as HSP90 inhibitors, in combination with agents that increase proteotoxic stress on tumor cells or agents that induce a biochemical rewiring of the chaperome. The proteotoxic agents are administered prior to administration of the chaperone proteins to achieve synergistic activity. |